|
|
 Previous Article | Table of Contents | Next Article 
Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination
for B-cell, non-Hodgkin's lymphoma
EL Nelson, X Li, FJ Hsu, LW Kwak, R Levy, C Clayberger and AM Krensky
Department of Medicine, Stanford University School of Medicine, CA, USA.
Patients with non-Hodgkin's B-cell lymphoma who received an antitumor
vaccine of idiotypic ig protein showed humoral and proliferative immune
responses. Because immunity to some antigens, including tumor antigens and
human pathogenic viruses, may be better correlated with the cytolytic
cellular immune response, we evaluated 16 non-Hodgkin's lymphoma patients
immunized with autologous idiotypic ig molecules for changes in
tumor-specific cytotoxic T-lymphocyte precursor (CTLp) frequency using
limiting dilution analysis. Eleven patients had a significant increase in
tumor-specific CTLp. Eight of these 11 patients remain without evidence of
disease or with stable minimal disease. In contrast, all five patients who
did not have a significant change in tumor-specific CTLp have developed
progressive disease. Patient vaccination with tumor associated protein
antigens can increase tumor- specific CTLp frequencies. The correlation of
increased tumor specific CTLp with freedom from progression is significant
at P = .002. This study indicates that measurement of CTLp frequencies are
relevant to the clinical evaluation of human tumor vaccines and suggests
that cell- mediated cytolytic immune responses may be an important
determinant of vaccine efficacy.
Volume 88,
Issue 2,
pp. 580-589,
07/15/1996
Copyright © 1996 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. A. McCormick, S. Reddy, S. J. Reinl, T. I. Cameron, D. K. Czerwinkski, F. Vojdani, K. M. Hanley, S. J. Garger, E. L. White, J. Novak, et al.
Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: Safety and immunogenicity in a phase I clinical study
PNAS,
July 22, 2008;
105(29):
10131 - 10136.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Houot and R. Levy
Therapeutic Vaccine for Lymphoma: Lessons Learned and Future Directions
Am. Assoc. Cancer Res. Educ. Book,
April 12, 2008;
2008(1):
3 - 11.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Huang, Y.-T. Ahn, L. McPherson, C. Clayberger, and A. M. Krensky
Interaction of PRP4 with Kruppel-Like Factor 13 Regulates CCL5 Transcription
J. Immunol.,
June 1, 2007;
178(11):
7081 - 7087.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Neelapu and L. W. Kwak
Vaccine Therapy for B-Cell Lymphomas: Next-Generation Strategies
Hematology,
January 1, 2007;
2007(1):
243 - 249.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Bertinetti, K. Zirlik, K. Heining-Mikesch, G. Ihorst, H. Dierbach, C. F. Waller, and H. Veelken
Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.
Cancer Res.,
April 15, 2006;
66(8):
4496 - 4502.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. S. Doubrovina, M. M. Doubrovin, S. Lee, J.-H. Shieh, G. Heller, E. Pamer, and R. J. O'Reilly
In vitro Stimulation with WT1 Peptide-Loaded Epstein-Barr Virus-Positive B Cells Elicits High Frequencies of WT1 Peptide-Specific T Cells with In vitro and In vivo Tumoricidal Activity
Clin. Cancer Res.,
November 1, 2004;
10(21):
7207 - 7219.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Brouha, J. Schustak, R. M. Badge, S. Lutz-Prigge, A. H. Farley, J. V. Moran, and H. H. Kazazian Jr.
Hot L1s account for the bulk of retrotransposition in the human population
PNAS,
April 29, 2003;
100(9):
5280 - 5285.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-i. Fujii, K. Shimizu, T. Shimizu, and M. T. Lotze
Interleukin-10 promotes the maintenance of antitumor CD8+ T-cell effector function in situ
Blood,
October 1, 2001;
98(7):
2143 - 2151.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Rinaldi, F. Ria, P. Parrella, E. Signori, A. Serra, S. A. Ciafrè, I. Vespignani, M. Lazzari, M. G. Farace, G. Saglio, et al.
Antibodies Elicited by Naked DNA Vaccination against the Complementary-determining Region 3 Hypervariable Region of Immunoglobulin Heavy Chain Idiotypic Determinants of B-lymphoproliferative Disorders Specifically React with Patients' Tumor Cells
Cancer Res.,
February 1, 2001;
61(4):
1555 - 1562.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. A. Riemersma, E. S. Jordanova, R. F. J. Schop, K. Philippo, L. H. J. Looijenga, E. Schuuring, and P. M. Kluin
Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites
Blood,
November 15, 2000;
96(10):
3569 - 3577.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Bercovici, M.-T. Duffour, S. Agrawal, M. Salcedo, and J.-P. Abastado
New Methods for Assessing T-Cell Responses
Clin. Vaccine Immunol.,
November 1, 2000;
7(6):
859 - 864.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. J. Weiner
The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides
J. Leukoc. Biol.,
October 1, 2000;
68(4):
455 - 463.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
F. Osterroth, A. Garbe, P. Fisch, and H. Veelken
Stimulation of cytotoxic T cells against idiotype immunoglobulin of malignant lymphoma with protein-pulsed or idiotype-transduced dendritic cells
Blood,
February 15, 2000;
95(4):
1342 - 1349.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Buhmann, A. Nolte, D. Westhaus, B. Emmerich, and M. Hallek
CD40-Activated B-Cell Chronic Lymphocytic Leukemia Cells for Tumor Immunotherapy: Stimulation of Allogeneic Versus Autologous T Cells Generates Different Types of Effector Cells
Blood,
March 15, 1999;
93(6):
1992 - 2002.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. McCormick, M. H. Kumagai, K. Hanley, T. H. Turpen, I. Hakim, L. K. Grill, D. Tuse, S. Levy, and R. Levy
Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants
PNAS,
January 19, 1999;
96(2):
703 - 708.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K.-M. Chang, N. H. Gruener, S. Southwood, J. Sidney, G. R. Pape, F. V. Chisari, and A. Sette
Identification of HLA-A3 and -B7-Restricted CTL Response to Hepatitis C Virus in Patients with Acute and Chronic Hepatitis C
J. Immunol.,
January 15, 1999;
162(2):
1156 - 1164.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Osterborg, Q. Yi, L. Henriksson, J. Fagerberg, S. Bergenbrant, M. Jeddi-Tehrani, U. Ruden, A.-K. Lefvert, G. Holm, and H. Mellstedt
Idiotype Immunization Combined With Granulocyte-Macrophage Colony-Stimulating Factor in Myeloma Patients Induced Type I, Major Histocompatibility Complex-Restricted, CD8- and CD4-Specific T-Cell Responses
Blood,
April 1, 1998;
91(7):
2459 - 2466.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. Dorfman, J. L. Schultze, A. Shahsafaei, S. Michalak, J. G. Gribben, G. J. Freeman, G. S. Pinkus, and L. M. Nadler
In Vivo Expression of B7-1 and B7-2 By Follicular Lymphoma Cells Can Prevent Induction of T-Cell Anergy But Is Insufficient to Induce Significant T-Cell Proliferation
Blood,
December 1, 1997;
90(11):
4297 - 4306.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. J. Hsu, C. B. Caspar, D. Czerwinski, L. W. Kwak, T. M. Liles, A. Syrengelas, B. Taidi-Laskowski, and R. Levy
Tumor-Specific Idiotype Vaccines in the Treatment of Patients With B-Cell Lymphoma --- Long-Term Results of a Clinical Trial
Blood,
May 1, 1997;
89(9):
3129 - 3135.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
